What is OKYO Pharma?
OKYO Pharma is a biopharmaceutical firm dedicated to advancing treatments for inflammatory eye diseases and ocular pain. Based in London, United Kingdom, the company's pipeline focuses on improving patient outcomes through innovative therapeutic solutions. The recent enterprise-level funding suggests a transition towards scaling its development and clinical trial operations.
How much funding has OKYO Pharma raised?
OKYO Pharma has raised a total of $5.8M across 3 funding rounds:
Stock Offering
$2.5M
Other Financing Round
$1.4M
Other Financing Round
$1.9M
Stock Issuance/Offering (2022): $2.5M, investors not publicly disclosed
Other Financing Round (2025): $1.4M, investors not publicly disclosed
Other Financing Round (2025): $1.9M, investors not publicly disclosed
What's next for OKYO Pharma?
With substantial enterprise-level funding and a recent strategic investment, OKYO Pharma is poised for accelerated growth. The company is expected to leverage this capital to advance its therapeutic candidates through late-stage development and clinical trials, potentially bringing new treatments to market for patients suffering from debilitating eye conditions. This financing round signals strong investor confidence in OKYO Pharma's scientific approach and market potential.
See full OKYO Pharma company page
